脑出血后降脂药物的使用
脑出血患者常合并高脂血症,且面临再出血、心血管疾病和缺血性卒中的风险,需重视血管事件的二级预防。然而,降脂治疗在脑出血人群中的获益与风险尚不明确,目前缺乏共识。本文综述相关文献,提出基于现有数据的治疗范式,并指出需专门随机试验来指导最优降脂策略。
要点
- 脑出血患者是高脂血症常见人群,且再出血、心血管事件和缺血性卒中风险高。
- 降脂治疗在脑出血患者中的获益与风险尚不明确,缺乏共识。
- 作者基于现有数据提出治疗范式,但强调需专门随机试验提供证据。
核心结论
- 目前尚无关于脑出血后高脂血症最佳管理策略的共识;作者基于现有数据提出治疗范式,但指出需要专门随机试验的证据来指导有脑出血史患者的最优降脂策略。
研究设计与样本
- 本文为综述,回顾相关文献以概述降脂治疗在脑出血这一脆弱人群中的竞争性风险与获益。
主要发现
- 流行病学研究提示高脂血症对脑出血具有保护作用,且强化降脂与脑出血风险增加相关。
- 现有降脂治疗在缺血性心脏和血管疾病患者中已得到充分研究,但仅少数随机试验纳入了极少数有脑出血史的患者。
- 因此,关于这些治疗在脑出血人群中的安全性和净获益,无法得出任何确定性结论。
临床怎么用
- 作者提出基于现有数据的治疗范式,但未据此给出具体推荐。
局限性
- 仅少数随机试验纳入了极少数有脑出血史的患者,限制了关于降脂治疗在脑出血人群中安全性和净获益的确定性结论。
- 目前尚无关于脑出血后高脂血症最佳管理策略的共识。
- 需要专门随机试验的数据来构建指导有脑出血史患者最优降脂策略的必要证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperlipidemia is common in patients with intracerebral hemorrhage (ICH). Accumulating evidence indicates that patients with ICH are at risk for future hemorrhage recurrence, cardiovascular disease, and ischemic stroke and highlights the importance of secondary prevention of vascular events after ICH. Although the benefits of intensive treatment of hyperlipidemia for reducing ischemic cardiac and vascular events in patients with ischemic stroke are well established, the benefit versus harm in patients with ICH are less clear. Epidemiological studies suggest that hyperlipidemia is protective against ICH and that intensive lowering of lipids is associated with increased risk for ICH. Similarly, although currently available lipid-lowering treatments have been thoroughly studied in patients with ischemic cardiac and vascular disease, only few randomized trials of these therapies included a very small number of patients with history of ICH. Thus, limiting any definitive conclusions regarding the safety and net benefit of these treatments in ICH populations. Currently, there is no consensus regarding the optimal strategy for management of hyperlipidemia after ICH. In this article, we review relevant literature to outline the competing risks and benefits of lipid-lowering treatments in this vulnerable patient population. We suggest a treatment paradigm based on available data but note that data from dedicated randomized trials are needed to build the necessary evidence to guide optimal lipid-lowering strategy in patients with a history of ICH.
引用
- Shoamanesh A, Selim M. Use of Lipid-Lowering Drugs After Intracerebral Hemorrhage. Stroke. 2022. PMID: 35658483. doi:10.1161/STROKEAHA.122.036889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。